Oral MRT-2359

Phase 2Small molecule

Oral MRT-2359 is one of 54 small molecule programs targeting Castration-Resistant Prostate Cancer (CRPC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Castration-Resistant Prostate Cancer (CRPC)Recruiting

CancerActive, not recruiting

Castration-Resistant Prostate Cancer (CRPC)Phase 2

Recruiting

CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

57 competitors in Cancer

#DrugCompanyPhaseTrials

Vemlidy

Gilead

Approved

1 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 3

Tecentriq

Roche

Phase 2

5 4

Keytruda

Merck & Co.

Phase 2

4 5

Afinitor

Novartis

Phase 2

3 6

Cotellic

Roche

Phase 2

3 7

Verzenio

Eli Lilly

Phase 2

2 8

Stivarga

Bayer

Phase 2

2 9

Imfinzi

AstraZeneca

Phase 2

2 10

Erivedge

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Active, not recruiting

Cancer

NCT05546268

Q2 2028

Phase 2Recruiting

Castration-Resistant Prostate Cancer (CRPC)

NCT07745361

Clinical

Trials by Indication[1]

Cancer1 trial

Study of Oral MRT-2359 in Selected Cancer Patients

Active, not recruiting·MMonte Rosa Therapeutics, Inc·Phase 1/2·NCT05546268·174 enrolled

Castration-Resistant Prostate Cancer (CRPC)1 trial

MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer

Recruiting·MMonte Rosa Therapeutics, Inc·Phase 2·NCT07745361·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Oral MRT-2359. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral MRT-2359 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral MRT-2359. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Monte Rosa Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMonte Rosa Therapeutics, Inc

Oral MRT-2359

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Cancer1 trial

Castration-Resistant Prostate Cancer (CRPC)1 trial

References

Drug Info

Quick Facts

Related News